Fiserv FISV
Technology · Information Technology Services · Synthos Deep Dive · 2026-07-03
The Overview
Fiserv is the plumbing behind card payments and banking. When you swipe a card at a small business, or your bank processes your account, Fiserv's technology (including Clover, its point-of-sale system) often runs it in the background. It is a huge, real business — about $21 billion in sales.
Here's the story: this used to be a market darling that went up almost every year. Then in the last twelve months the stock collapsed by about 70% — one of the worst falls in the S&P 500 — because its sales stopped growing and even started shrinking slightly, and it kept less profit than before. So now the stock looks very cheap (you pay only about $6 for every $1 of yearly profit, versus $20+ for a typical company). But cheap can be a trap if the business keeps getting worse.
Our verdict is Watch — not "buy," not "avoid." The price already reflects a lot of bad news, but the company has not yet proven the bleeding has stopped. We want to see one or two quarters where sales stabilize before calling it a buy.
Here's what our three scores mean in everyday terms:
- Downside Risk 7/10 (elevated). It is cheap, but it carries a lot of debt and the business is still shrinking, so more bad news could still hurt.
- Growth Quality 4/10 (below average). Growth has actually gone slightly negative and profit margins are shrinking — the opposite of a healthy growing company right now.
- Exponential Potential 2/10 (very low). This is a big, slow, declining business — there is no realistic path to it multiplying in value soon.
The one big worry: the turnaround under new management simply doesn't work — sales keep sliding and profits keep eroding — in which case "cheap" gets cheaper.
Putting a number on it: our fair-value estimate is $58 against a current price of $53.18 — real upside if our numbers are right.
Our summary metrics
Cheap on earnings but 3.6x net-debt/EBITDA, a broken growth story, revenue now shrinking, and a -78% drawdown.
Organic revenue turned NEGATIVE (-4% Q1'26); margins compressing; ~1-3% FY26 organic guide is a stall, not growth.
Decelerating into outright decline; no acceleration, no room-to-run catalyst — the opposite of exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Decelerating into outright decline; no acceleration, no room-to-run catalyst — the opposite of exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $69.17 (high $91 / low $46; 35 Buy · 25 Hold · 0 Sell) — context, not our anchor |
| Valuation | 8.3× trailing GAAP EPS · ~6.4× FY26E adj EPS · ~5.9× FY27E · EV/S 2.7× · EV/EBITDA 7.1× · FCF yield ~15% |
| Technicals | Severe downtrend — $52.33, −78% off the 52-wk high, below 50/200-DMA, RSI 48, −70% 12-mo (SPY +21%) |
| Conviction | Low — 0 KB voices, 0 claims. Rated on financials + quant only |
| Position sizing | If owned at all, a small ~1–2% deep-value/turnaround satellite — not a core holding |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for FISV — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $53.18, 3% above the 50-day average ($52), 9% below the 200-day average ($59) — a mixed trend. 62% below the 52-week high of $138, 13% above the 52-week low of $47.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $53.18 is currently inside the band (band $51–$55).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 52.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.06, negative momentum.
Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago
Solid = FISV · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Fiserv, Inc. (NASDAQ: FISV) is a ~40-year-old global provider of payments and financial-services technology, headquartered in Milwaukee/Brookfield, Wisconsin, with ~38,000 employees. Its franchise spans merchant acquiring and point-of-sale (the fast-growing Clover platform and Carat omnichannel), card issuer processing and network services, and core account processing / digital banking for financial institutions. Fiscal year ends December 31.
Fiserv is mid-reorganization. The FMP profile describes three product segments (Acceptance, Fintech, Payments), but the Q1'26 earnings release now reports on two segments — Merchant Solutions and Financial Solutions — as new CEO Michael Lyons executes the "One Fiserv Action Plan." That segment realignment itself signals a company in transition.
Revenue mix (from filings; note the segmentation keeps changing):
- FY2024 (latest full-year product split): Processing & Services $16.64B (81%) · Product $3.82B (19%). The business is overwhelmingly recurring processing revenue — a genuine structural strength.
- FY2023 legacy segments: Acceptance $6.94B · Payments & Industry Products $6.70B · Fintech $3.17B.
- Q1'26 (new reporting): GAAP revenue flat in Merchant Solutions, −5% in Financial Solutions; organic −1% Merchant, −6% Financial. The Financial Solutions (bank/core) side is where the decline is concentrated.
- Geography: overwhelmingly US (the one older geo split available, FY2020, shows US ~40% of a much smaller international-reported base; today the company is majority-US by revenue). US concentration is a stability strength but limits geographic diversification.
The recurring, mission-critical nature of the revenue is real. The problem is that the growth has evaporated — see §5.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of FISV in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0. No independent voice in our panel has issued a traceable claim on this name.
That means this deep dive borrows zero conviction from experts — there is no bull or bear thesis to cite, and we will not manufacture one. The verdict is driven entirely by the reported financials, the analyst estimates (FMP consensus, labeled as estimates), and Synthos's own quant/valuation framework. Where the Street is cited below (35 Buy / 25 Hold, PT consensus $69.17), that is sell-side context, not a Synthos-reconciled conviction signal.
Read this section as a caution, not an endorsement: names with no KB breadth get the benefit of no doubt. The bar for a Buy is entirely on the fundamentals, and today FISV does not clear it.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 7 · Elevated | Optically cheap (6× fwd EPS, ~15% FCF yield, beta 0.79) — but net-debt/EBITDA 3.6×, a shrinking core, compressing margins, and a −78% drawdown that says the market has lost faith. Cheapness is not the same as safety. |
| Growth Quality | 4 · Below average | Organic revenue −4% in Q1'26; GAAP operating margin fell to 18.3% from 27.2%; adjusted EPS −16% YoY. FY26 organic guide of 1–3% is a stall. The recurring base and ROIC are real positives keeping this off the floor. |
| Exponential Potential | 2 · Very Low | Growth has decelerated through zero into decline. No acceleration, no under-penetrated TAM story that scales the whole company, $28B cap already large. The opposite of exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | The "One Fiserv" turnaround works: organic growth re-accelerates toward mid-single digits by FY27, Clover keeps compounding, margins stabilize. FY27E adj EPS ~$8.90 (near cons) and a sentiment repair to a ~9.5× multiple as the market re-rates a de-risked compounder. | ~$85 (+62%) |
| Base (our anchor) | Guidance roughly holds: FY26 adj EPS ~$8.15 (mid of $8.00–$8.30), low-single-digit organic growth, no further margin cliff. A stabilized-but-slow FinTech earns a still-depressed ~7× on ~$8.30 FY27E adj EPS. | ~$58 (+11%) |
| Bear | The turnaround stalls: organic revenue stays negative, Financial Solutions keeps sliding, margins compress further, leverage limits buybacks. FY27E adj EPS slips to ~$7.50 and the multiple stays distressed at ~4.5×. | ~$34 (−35%) |
Synthos fair value = the base case, ~$58 (+11%), with the full $34–$85 span as the honest range. Our base sits below the Street's $69.17 consensus: we are less willing to underwrite the turnaround before it shows in the numbers, and the wide gap between our base and the Street's $91 high reflects genuine uncertainty, not conviction. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). FISV is neither right now — it is a decelerating former-compounder in a turnaround:
- Forward "growth": revenue CAGR FY25→FY30E is only ~2.2% ($21.19B → $23.59B on consensus estimates) — barely above inflation. EPS is projected to compound faster (FY26E adj ~$8.12 → FY30E ~$15.9 consensus) but that path leans heavily on buybacks and margin recovery that have not yet materialized.
- Acceleration (the 2nd derivative) is negative through zero: revenue growth ran +14% (FY21) → +9% (FY22) → +8% (FY23) → +7% (FY24) → +3.6% (FY25) → and organic turned −4% in Q1'26. This is a textbook deceleration, and it has now crossed into outright decline in the core.
- Room to run: payments is a large TAM, but FISV is a $28B incumbent losing organic share in its bank-technology segment, not an under-penetrated challenger. There is no "10× the addressable base" story here — the growth constraint is competitive and self-inflicted, not runway.
- Reinvestment runway: FCF is real (~$4.3B FY25, ~15% FCF yield) and capital returns are large, but reinvestment has not produced growth — the tell that this is a value/turnaround case, not an exponential one.
Exponential Potential: Very Low (2/10). If you own FISV, own it as a cheap-turnaround/mean-reversion bet on multiple repair and buybacks, explicitly not for exponential growth. That is the honest framing.
5. Financials (real numbers — FMP annual/quarterly + Q1'26 release)
- Revenue: FY25 $21.19B, +3.6% (FY24 $20.46B, +7.1% on FY23 $19.09B). The multi-year deceleration is the whole story: growth halved from FY24 to FY25 and has now gone negative on an organic basis.
- Quarterly trajectory (the deterioration): the FMP quarterly revenue is choppy on a reported basis, but the cleaner read is the company's own organic figure — Q1'26 organic revenue −4%, GAAP revenue −2% YoY, adjusted EPS −16% YoY. This is the print that broke the stock.
- Margins (compressing): FY25 gross ~58% TTM, EBITDA margin ~37%. But Q1'26 GAAP operating margin collapsed to 18.3% from 27.2% a year earlier, and adjusted operating margin fell to 29.7% from 37.8%. Margin erosion, not just slow growth, is the second red flag.
- Earnings: FY25 GAAP net income $3.48B, EPS $6.34 (diluted). Q1'26 GAAP EPS $1.07 (−29% YoY); adjusted $1.79 (−16%).
- Cash flow: FY25 operating CF $6.10B, capex −$1.76B, FCF $4.34B — a ~15% FCF yield at today's cap. This is the ballast: even in decline, FISV gushes cash, funding a large buyback ($5.9B repurchased in FY25; 3.3M shares / $200M in Q1'26).
- Balance sheet (the risk): total debt $29.1B, net debt $28.3B, net-debt/EBITDA ~3.6× — meaningfully levered. Goodwill + intangibles of ~$47.9B exceed total equity of ~$25.8B (tangible book is negative). Interest coverage ~3.4×. The leverage is serviceable against $6B operating cash flow but leaves little room for a deeper downturn and constrains how aggressively management can defend the stock with buybacks.
The picture: a cash-rich, recurring-revenue franchise whose growth engine has stalled and whose margins are eroding, carrying real leverage. Cheap for reasons.
6. Valuation — priced in or room?
On earnings, FISV is genuinely inexpensive: 8.3× trailing GAAP EPS ($6.34), ~6.4× FY26E adjusted EPS (~$8.15 guide midpoint), ~5.9× FY27E, EV/EBITDA 7.1×, EV/sales 2.7×, and a ~15% free-cash-flow yield. FMP's letter rating is A- and its DCF score is high — the model sees value. For a business still generating $4B+ of FCF, these are distressed-adjacent multiples.
The bear's rebuttal is that the multiple is low because the growth is gone: a payments processor growing 1–3% organically with compressing margins and 3.6× leverage arguably deserves a high-single-digit P/E, not the 20×+ it once carried. The re-rating from ~$175 to ~$52 already did most of that work. The question for the buyer is whether ~6× forward earnings over-discounts a stabilizing (not dying) franchise. Reverse read: at $52 the market is pricing near-zero durable growth and no margin recovery; even a modest turnaround (organic back to mid-single digits, margins holding) supports our ~$58 base and the Street's $69. Street targets (context): consensus $69.17, high $91, low $46 — our $58 base is deliberately below consensus because we will not pay up for a turnaround before Q2 confirms stabilization. Not obviously a value trap, not yet obviously a bargain — a show-me valuation.
7. Technicals (from the tech block)
- Trend: severe downtrend. $52.33 sits below the 50-DMA ($54.86) and far below the 200-DMA ($70.70), with the 50 below the 200 (death-cross posture). MACD −1.46 (negative).
- Location: −78% off the 52-week high ($175.55) and only +11% off the 52-week low ($47.18) — pinned near the lows, with a max drawdown from peak of −78%. This is a broken chart, not a base yet.
- Momentum: RSI(14) 48 — neutral, neither oversold nor overbought, so no mechanical bounce signal.
- Relative strength (the tell): FISV −70% 12-mo vs SPY +21% and QQQ +30%; −22.5% 6-mo and −5.6% 3-mo while SPY rose. Persistent, brutal underperformance of both the market and the Nasdaq — the market has repriced this name violently.
- Read: technicals do not confirm a turn. There is no uptrend, no golden cross, no positive relative strength to lean on. A technician would want to see the stock reclaim its 50-DMA and post positive relative strength before trusting a bottom — consistent with our Watch.
8. Moat & competitive position
Fiserv's moat is real but eroding at the edges: (1) high switching costs — core banking and payment processing are mission-critical, deeply embedded systems that clients rarely rip out; (2) scale in card issuer processing and merchant acquiring; (3) Clover, a genuinely strong, growing POS/business-management platform that is the best part of the story. The offset: the Financial Solutions (bank technology) segment is losing organic revenue, competition in merchant acquiring is intense (Stripe, Square/Block, Adyen, Toast on the modern-stack side), and the legacy core-banking business faces slow secular pressure. A moat that keeps the revenue sticky but no longer drives it higher.
Peer set (FMP-supplied; mixed IT-services group, market cap): the closest real comp is FIS (Fidelity National Information Services) $21.6B — the direct core-processing/payments peer, also de-rated. The rest of the FMP list is a looser "IT services" basket: Cognizant $19.9B, Broadridge $16.6B, CDW $17.0B, HPE $54.6B, Ericsson $35.7B, Leidos $13.7B, Gartner $9.1B, Wipro $19.8B, ASE Tech $91.9B. Not shown but most relevant competitively: Global Payments and Block/Square. Against FIS specifically, FISV still carries the stronger asset in Clover.
9. Management, capital allocation & guidance
- Leadership transition: Michael Patrick Lyons is CEO, executing the "One Fiserv Action Plan" and "Project Elevate" productivity initiative. New management mid-turnaround adds execution risk and option value.
- Capital allocation: no dividend; capital return is entirely via buyback ($5.9B repurchased FY25; $200M / 3.3M shares Q1'26). Buying back stock at ~6× earnings is accretive if the business stabilizes — but the 3.6× leverage limits how aggressively they can lean in, and repurchasing a falling stock has destroyed optical value over the past year.
- Insider activity: the recent Form 4s (filed 2026-07-01) are routine director deferred-compensation notional-unit awards, not open-market discretionary buys or sells — no signal either way.
- Management's own guidance (half-weighted — their own book): Guidance IS available from the Q1'26 earnings release (SEC 8-K, dated 2026-05-05). Management affirmed FY2026 organic revenue growth of 1% to 3% and adjusted EPS of $8.00 to $8.30. CEO Lyons: "we remained in execution mode, delivering results in line with the expectations we shared in February… advancing the One Fiserv Action Plan." CFO Paul Todd: "First quarter results were supported by stable underlying account and volume trends… We remain confident in our full-year guidance." Management also pointed to a May 14 Investor Day for its medium-term financial outlook. Synthos weighting: this is management's self-interested framing (half-weight). The affirmation is reassuring, but "1–3% organic" is a stall dressed as stability, and margins fell hard in the same quarter — take the confidence with salt.
10. Catalysts & what to watch
- Next earnings: 2026-07-22 (Q2'26; Street EPS $1.91, revenue ~$5.04B). The single most important print for this call — does organic revenue stabilize or keep sliding, and do margins stop falling?
- Medium-term outlook from the May 14 Investor Day: management's framing of the turnaround glide-path (already delivered; watch for follow-through vs. the plan).
- Clover volume/revenue growth: the strongest asset — sustained growth here is the bull's foundation.
- Financial Solutions segment: the source of the organic decline — arresting the −6% organic slide is the base case's key requirement.
- Deleveraging / buyback pace: whether FCF is used to repair the balance sheet or defend the stock.
Thesis tripwires (what would change the call): Upgrade to Buy if Q2/Q3 show organic revenue back to positive AND adjusted operating margin stabilizing. Downgrade toward Avoid if organic decline deepens, margins compress further, or FY26 guidance is cut.
11. Key risks
- Turnaround failure (the core risk): organic revenue stays negative and margins keep eroding — "cheap" becomes cheaper. No expert conviction to lean on; the numbers must do the work.
- Leverage: 3.6× net-debt/EBITDA with negative tangible book (goodwill/intangibles > equity) — limited cushion in a deeper downturn, constrained buyback firepower.
- Competitive / secular: modern-stack acquirers (Stripe, Block, Adyen, Toast) and slow legacy core-banking pressure on the Financial Solutions segment.
- Execution under new management: a CEO-led restructuring ("One Fiserv," "Project Elevate") is inherently uncertain.
- No KB coverage: Synthos has zero independent expert claims on this name — lower confidence in either direction than for a well-covered name.
- Value-trap risk: low multiples can persist for years if growth never returns.
12. Verdict, position sizing & monitoring
Watch. FISV is a cheap, cash-generative, mission-critical payments franchise that has been repriced ~78% off its high because its growth engine stalled and turned organically negative while margins compressed. At ~6× forward earnings and a ~15% FCF yield it is statistically cheap, and management has affirmed guidance — but organic revenue is still shrinking, leverage is real at 3.6×, the chart is broken, and there is no expert conviction in our KB to underwrite a turn. This is a show-me situation: the value is visible, the catalyst (stabilization) is not yet confirmed.
- Sizing: if owned at all, a small ~1–2% deep-value/turnaround satellite, not a core position — and only for investors comfortable buying a falling knife on valuation. Most should wait for the Q2 print.
- Monitoring: the 2026-07-22 Q2 earnings is the decision point. Upgrade on confirmed organic + margin stabilization; downgrade on a deeper slide or guidance cut.
- Single biggest risk: the turnaround simply doesn't work — organic decline and margin erosion persist, validating the de-rating.
Verdict logged as a tracked Synthos call as of 2026-07-03 at $52.33.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert coverage. This note is fundamentals- and quant-driven only; no conviction is borrowed from panel voices, and none is fabricated. Where sell-side data appears (35 Buy / 25 Hold, PT $69.17) it is labeled as Street context, not a Synthos signal.
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · Q1'26 guidance from SEC 8-K dated 2026-05-05. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: FISV management's affirmed FY26 guidance (1–3% organic, $8.00–$8.30 adj EPS) is management's own book, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").